FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer

On April 8, the US Food and Drug Administration (FDA) approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer.

For more information, read the FDA announcement.

Posted on 4/08/25